How to buy Emergent BioSolutions stock - 15 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Emergent BioSolutions stock

Own Emergent BioSolutions stock in just a few minutes.

Emergent BioSolutions Inc is a drug manufacturers-specialty & generic business based in the US. Emergent BioSolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent BioSolutions employs 2,200 staff and has a trailing 12-month revenue of around USD$1.6 billion.

How to buy shares in Emergent BioSolutions

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Emergent BioSolutions. Find the stock by name or ticker symbol: EBS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Emergent BioSolutions reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Emergent BioSolutions, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Emergent BioSolutions. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Emergent BioSolutions share price

Use our graph to track the performance of EBS stocks over time.

Emergent BioSolutions shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$60.46 - USD$137.61
50-day moving average USD$94.6
200-day moving average USD$96.8742
Wall St. target priceUSD$114.5
PE ratio 14.3095
Dividend yield N/A (0%)
Earnings per share (TTM) USD$5.67

Buy Emergent BioSolutions shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Emergent BioSolutions stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Emergent BioSolutions under- or over-valued?

Valuing Emergent BioSolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent BioSolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Emergent BioSolutions's P/E ratio

Emergent BioSolutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Emergent BioSolutions shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Emergent BioSolutions's PEG ratio

Emergent BioSolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent BioSolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Emergent BioSolutions's EBITDA

Emergent BioSolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$604.5 million.

The EBITDA is a measure of a Emergent BioSolutions's overall financial performance and is widely used to measure a its profitability.

Emergent BioSolutions financials

Revenue TTM USD$1.6 billion
Operating margin TTM 31.79%
Gross profit TTM USD$857.6 million
Return on assets TTM 11.86%
Return on equity TTM 24.07%
Profit margin 19.62%
Book value $27.25
Market capitalisation USD$4.3 billion

TTM: trailing 12 months

Shorting Emergent BioSolutions shares

There are currently 2.6 million Emergent BioSolutions shares held short by investors – that's known as Emergent BioSolutions's "short interest". This figure is 9.4% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Emergent BioSolutions shares can be evaluated.

Emergent BioSolutions's "short interest ratio" (SIR)

Emergent BioSolutions's "short interest ratio" (SIR) is the quantity of Emergent BioSolutions shares currently shorted divided by the average quantity of Emergent BioSolutions shares traded daily (recently around 735696.06741573). Emergent BioSolutions's SIR currently stands at 3.56. In other words for every 100,000 Emergent BioSolutions shares traded daily on the market, roughly 3560 shares are currently held short.

However Emergent BioSolutions's short interest can also be evaluated against the total number of Emergent BioSolutions shares, or, against the total number of tradable Emergent BioSolutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Emergent BioSolutions's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Emergent BioSolutions shares in existence, roughly 50 shares are currently held short) or 0.0684% of the tradable shares (for every 100,000 tradable Emergent BioSolutions shares, roughly 68 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Emergent BioSolutions.

Find out more about how you can short Emergent BioSolutions stock.

Emergent BioSolutions share dividends

We're not expecting Emergent BioSolutions to pay a dividend over the next 12 months.

Emergent BioSolutions share price volatility

Over the last 12 months, Emergent BioSolutions's shares have ranged in value from as little as $60.46 up to $137.61. A popular way to gauge a stock's volatility is its "beta".

EBS.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent BioSolutions's is 1.1655. This would suggest that Emergent BioSolutions's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Emergent BioSolutions overview

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site